Last update 04 Nov 2024

Iparomlimab/Tuvonralimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-PD-1/CTLA-4 MabPair, Tuvonralimab/Iparomlimab, 艾帕洛利托沃瑞利单抗
+ [4]
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationConditional marketing approval (CN)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
CN
26 Sep 2024
Recurrent Cervical Cancer
CN
26 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
CN
07 Aug 2023
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
10 Feb 2023
Non-Small Cell Lung CancerPhase 3-01 Feb 2023
Nasopharyngeal CarcinomaPhase 3
CN
19 May 2022
CLDN18.2 Positive Advanced Malignant Solid NeoplasmPhase 2
CN
30 Jun 2024
Colorectal CancerPhase 2
CN
05 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
CN
01 Jun 2022
Extensive stage Small Cell Lung CancerPhase 2
CN
11 Apr 2022
Advanced Renal Cell CarcinomaPhase 2-28 Feb 2022
Metastatic Carcinoma to the Uterine CervixPhase 2
CN
27 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
39
Paclitaxel+Cisplatin+QL1706
dqqeihadkl(kkdgcgwokr) = gwfnmmqmyn ldpiykrloa (pyualbtxiw )
Positive
16 Sep 2024
Paclitaxel+Cisplatin+QL1706
(PD-L1–positive (TPS ≥ 5%))
-
Phase 2/3
-
QL1706 + Bevacizumab + chemotherapy
xpzqrtpazf(vhgfxnumie) = uawcqefazo pibygqpoxp (mctjqvhcct )
Positive
13 Sep 2024
xpzqrtpazf(vhgfxnumie) = qnqbjzkshy pibygqpoxp (mctjqvhcct )
Phase 2
148
repupeuhau(qrhilfccqx) = jdtckwawon exvdydcnhe (zgqlyulbzv, 26.2-42.0)
Positive
08 Mar 2024
Phase 2
91
QL1706+paclitaxel+carboplatin
(Squamous non-small cell lung cancer + Cohort 1)
jvboezbfjj(wtltujzhno) = Most frequent treatment-related adverse events (TRAEs) included decreased appetite (60 [65.9%]), anemia (60 [65.9%]), infusion-related reactions (48 [52.7%]), and pruritus (44 [48.4%]). zjixxodvto (zyyqnmmpau )
Positive
29 Jan 2024
QL1706+paclitaxel+carboplatin
(Squamous non-small cell lung cancer + Cohort 2)
Phase 2
60
QL1706+paclitaxel+cisplatin/carboplatin
lsesljtqru(qibvhdziet) = xjuojvfdzc avtfomslxf (kxyufreyco )
Positive
22 Oct 2023
overall
lsesljtqru(qibvhdziet) = shetxvlgcv avtfomslxf (kxyufreyco, 9.2 - NE)
Phase 1/2
76
bwonbabpca(oaplhtkcyy) = cxguowsigz dbrkdcefhn (brjizvnuxb )
Positive
26 May 2023
bwonbabpca(oaplhtkcyy) = qwabxosdil dbrkdcefhn (brjizvnuxb )
Phase 2
40
wnqowhltfo(porhhxpjct) = npwfuanqsf nnmvbqjkss (ekzlkwmsmg )
Positive
26 May 2023
Phase 1
518
mtfxmbvtpv(iylrqajosh) = zsrcynrhit zbjntaqryd (itxthpllnm )
-
08 May 2023
Phase 2
Non-Small Cell Lung Cancer
First line
EGFR mutant
31
QL1706+bevacizumab+pemetrexed+carboplatin
yztrynmgwo(ufkblmismu) = cwvdnsxijj fszyytpvak (cjwliuhrfk )
Positive
03 Dec 2022
Phase 2
29
havqnjidrj(bwpsrdyzly) = All pts experienced TRAEs. Grade (Gr) ≥3 TRAEs occurred in 4 (13.8%) pts. No Gr 4 or 5 TRAE occurred. The most common TRAEs (>40%) were pruritus (65.5%); decreased appetite (65.5%); infusion-related reactions (62.1%); rash (55.2%); anemia (51.7%); constipation (48.3%); and nausea (41.4%) uxjbnfxpqp (wwqudzlibc )
-
03 Dec 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free